To become a reference European Biotechnology company with the capabilities to develop and bring to market desperately needed therapies in complex or untreated diseases

Medibiofarma discovers and develops new chemical entities (NCEs) with clinical proof-of-concept  data in human patients

Medibiofarma focuses internal resources in the followings areas:

• Drug Design
• Medicinal and Synthetic Chemistry
• In Vitro Pharmacology
• Intellectual Property
• Clinical Trials
• Business Development

The remaining activities for the full characterization and nomination of a development candidate, such as in vivo pharmacology, toxicology and IND-enabling studies  are carried out through partnerships with several companies (CROs), Research Centers and Universities.